{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-045328","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.803144+00:00","generated_at":"2026-06-05T15:12:16.125185+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Seres Therapeutics appoints Marella Thorell as CFO; David Arkowitz retires March 15","bullets":["Marella Thorell named EVP and CFO effective March 25, 2024; David Arkowitz retires as CFO on March 15.","CEO Eric Shaff serves as interim principal financial and accounting officer from March 15 to March 25.","Thorell receives $480,000 base salary, $80,000 sign-on bonus, and option to purchase 700,000 shares.","Arkowitz gets 12 months base salary, COBRA coverage, and $500/hour advisory fee for up to 10 hours/month for 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-045328","json":"https://secwatch.observer/filing/0001193125-24-045328.json","markdown":"https://secwatch.observer/filing/0001193125-24-045328.md","text":"https://secwatch.observer/filing/0001193125-24-045328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/0001193125-24-045328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/d784620d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:12:16.125185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3eb91e3fc3","claim":"David Arkowitz retired as Chief Financial Officer at Seres Therapeutics, Inc..","evidence_excerpt":"Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/0001193125-24-045328-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6c14b8b201","claim":"Marella Thorell was appointed as Executive Vice President and Chief Financial Officer at Seres Therapeutics, Inc..","evidence_excerpt":"On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524045328/0001193125-24-045328-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}